NCT01892527 2022-09-09
Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Istituto Clinico Humanitas
Phase 2 Completed
Clinical Trials
10 trialsNCT01075048 2021-04-08
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT01755767 2021-04-06
METIV-HCC
Daiichi Sankyo
Phase 3 Completed
NCT01178411 2021-03-10
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Completed
NCT02029157 2017-10-09
JET-HCC
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT01152645 2017-03-15
ARQ 197-004
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01611857 2016-11-23
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00558207 2013-02-25
A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed
NCT00802555 2012-07-12
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed